Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 23, 2025—Seegene will unveil its fully automated PCR testing system, CURECA, and its data analytics platform, Stagora, at the Association for Diagnostics and Laboratory Medicine annual meeting, July 27–31, in Chicago.
July 17, 2025—Quest Diagnostics has launched a diagnostic laboratory test for the Oropouche virus, an emerging virus in the Americas that is spread to people by infected biting midges and some species of mosquitoes.
July 15, 2025—Waters Corp. and BD announced a definitive agreement to combine BD’s biosciences and diagnostic solutions business with Waters in a deal valued at approximately $17.5 billion.
July 11, 2025—Streck has launched its inaugural Liquid Biopsy Accelerator Grant aimed to support innovative research in blood-based early cancer detection and other noninvasive diagnostic strategies.
July 10, 2025—Gestalt showcased its AI-powered pathology platform, PathFlow, at the DICOM WG-26 2025 Connectathon, cosponsored by the Digital Pathology Association and European Society of Digital and Integrative Pathology.
July 8, 2025—Bio-Rad Laboratories has launched four Droplet Digital PCR platforms, which include the company’s QX Continuum ddPCR system and the QX700 series of ddPCR platforms, acquired as part of Bio-Rad’s recent purchase of Stilla Technologies.
July 7, 2025—Randox has launched the Evidence RABTA (random access biochip technology analyzer), capable of processing up to 60 samples per hour and delivering up to 2,640 test results per hour.
July 3, 2025—The FDA has approved Thermo Fisher Scientific’s Oncomine Dx Express test on the Ion Torrent Genexus Dx integrated sequencer as an in vitro diagnostic assay for use as a companion diagnostic for Dizal’s Zegfrovy (sunvozertinib) to identify patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
July 1, 2025—PathAI has received 510(k) clearance from the U.S. Food and Drug Administration for its AISight Dx digital pathology image-management system for use in primary diagnosis in clinical settings.
June 30, 2025—Datroway (datopotamab deruxtecan-dlnk) has been approved in the United States for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy.
